Drug Trial Radar · NCT05585931
Effect of TPN171H on Spermatogenesis
Last checked: Nov 20, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Nov 15, 2022
Primary completion
Dec 16, 2022
Study completion Dec 16, 2022
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in healthy male subjects.
Conditions
- Erectile Dysfunction
Interventions
TPN171H 10mgDrug
Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
TPN171H PlaceboDrug
Subjects were given Placebo with 240 mL warm water under fasting condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect on semen functionTime frame: 1.5 hours after taking the medicine
- Seminal plasma exposureTime frame: 1.5 hours after taking the medicine
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.